MEET YOUR NEW AI CLINICAL ASSISTANT /// GET EARLY ACCESS
Our collection of offerings uncover unique insights that empower you to customize treatment for individual patients, throughout their cancer journey.
CONTACT usWe deliver a comprehensive view of your patients through our tissue and liquid DNA profiling, somatic and germline testing, tumor-normal matched profiling and RNA sequencing.
We leverage our growing database to create specialized algorithms like Homologous Recombination Deficiency (HRD), Tumor Origin (TO), and DPYD, with more algorithms in development.
We bring just-in-time clinical trial options to patients based on clinical and molecular data, for enrollment at your institution, through our TIME Trial Program—in days instead of months.
We are developing AI capabilities to help pathologists find actionable markers in specimens to identify potential patients for clinical trials or precision therapeutics.
We are committed to making our tests accessible for those in financial need. Most applicants who qualify pay no more than $100.
We bring our proprietary AI-enabled service platform to you in real-time, through our novel technology and online capabilities.
We provide select participating institutions with access to technical support, customized to meet the unique needs and goals of your cancer center.
We offer easy access to current treatment options and relevant insights through our integration and connectivity capabilities.
We have established relationships that span from community practices to more than 50% of all academic medical centers in the United States.
5K+
oncologists rely on Tempus as their precision medicine partner
20K+
patients have been identified for potential enrollment into clinical trials in our network
6M+
de-identified research records
20+
operational countries across North, Central, South America, Europe, Middle East, and Asia
This study demonstrates the success that Tempus’ TIME Trial Program had with Sermonix’s Elaine II trial for patients with ESR1-mutant, estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.
Read moreRNA-based, whole-exome sequencing provides a complementary method for fusion detection, and may improve the identification of actionable variants.
Read moreDual tissue and ctDNA testing, “dual testing”, improved identification of actionable variants compared with either modality alone.
Read moreExtensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.
Read moreActionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.
Read moreThis study found that Tumor-normal (T/N) matched next-generation sequencing (NGS) has multiple advantages including enhanced variant classification and incidental germline variant discovery that may be missed with a guidelines-based approach.
Read moreHear from lung cancer specialists on their view of best practices for implementing personalized NGS testing approaches into clinical care.
Watch nowBroad panel NGS testing coupled with AI-enabled data continues to evolve and expand delivery of personalized solutions within breast cancer care.
Watch nowThe utility of whole transcriptome RNA sequencing now and in the future
Read moreTempus founder and CEO Eric Lefkofsky discusses the state of precision medicine with reporter Yasmeen Abutaleb.
Read moreThe newest Tempus algorithmic predictive test assesses for relevant mutations in the DPYD gene and helps physicians better identify patients at potential risk for toxicity to certain chemotherapies.
Read moreAs part of the collaboration, Cedars-Sinai is leveraging Tempus’ genomic sequencing tests and data structuring capabilities for a variety of clinical and research efforts.
Read moreOur Tempus xT assay is designed to detect actionable oncologic targets by sequencing tumor samples with matched normal saliva or blood samples, when available.
Read moreOur non-invasive Tempus xF liquid biopsy assay detects cell-free DNA (cfDNA) in blood specimens of advanced solid tumor patients.
Read moreWe offer an easy ordering process which allows you to order any of somatic and germline panels along with our add-on tests like HRD, TO and DPYD.
View here“Having Tempus in my fight for cancer… it’s incredible.”
“I already know–thanks to [Tempus] testing–my first, second, and third lines of defense.”
“Without Tempus I couldn’t have reached any solution. It’s a new hope in life, for cancer.”
Every new test and data point strengthens our algorithms, predictions, and recommendations to improve treatment options for future patients.
